Cambridge, MA, United States of America

Brian Dolinski

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 8.7

ph-index = 3

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Brian Dolinski: Innovator in Protein Regulation and Immunotherapy

Introduction

Brian Dolinski is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of protein regulation and immunotherapy, holding a total of 5 patents. His work focuses on developing innovative methods and compositions that enhance the controlled expression of proteins, which is crucial for various therapeutic applications.

Latest Patents

Among his latest patents, one notable invention is related to DHFR tunable protein regulation. This invention encompasses compositions and methods for the regulated and controlled expression of proteins. Another significant patent involves PDE5 compositions and methods for immunotherapy, which also relates to the regulated expression of proteins. This patent provides methods for inducing anti-cancer immune responses in a subject, showcasing the potential impact of his work on cancer treatment.

Career Highlights

Brian Dolinski is currently associated with Obsidian Therapeutics, Inc., where he continues to push the boundaries of scientific research and innovation. His expertise in protein regulation and immunotherapy has positioned him as a key figure in the biotechnology sector.

Collaborations

Some of his notable coworkers include Vipin Suri and Dexue Sun, who collaborate with him on various projects within the company.

Conclusion

Brian Dolinski's contributions to the fields of protein regulation and immunotherapy highlight his innovative spirit and dedication to advancing medical science. His patents reflect a commitment to developing solutions that can significantly impact patient care and treatment outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…